GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » THC Therapeutics Inc (OTCPK:THCT) » Definitions » 3-Year EPS without NRI Growth Rate

THC Therapeutics (THC Therapeutics) 3-Year EPS without NRI Growth Rate : 48.50% (As of Jul. 2023)


View and export this data going back to 2007. Start your Free Trial

What is THC Therapeutics 3-Year EPS without NRI Growth Rate?

THC Therapeutics's EPS without NRI for the three months ended in Jul. 2023 was $-0.00.

During the past 3 years, the average EPS without NRI Growth Rate was 48.50% per year. During the past 5 years, the average EPS without NRI Growth Rate was 41.00% per year. During the past 10 years, the average EPS without NRI Growth Rate was 30.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of THC Therapeutics was 70.70% per year. The lowest was -229.90% per year. And the median was 38.20% per year.


Competitive Comparison of THC Therapeutics's 3-Year EPS without NRI Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, THC Therapeutics's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


THC Therapeutics's 3-Year EPS without NRI Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, THC Therapeutics's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where THC Therapeutics's 3-Year EPS without NRI Growth Rate falls into.



THC Therapeutics 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


THC Therapeutics  (OTCPK:THCT) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


THC Therapeutics 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of THC Therapeutics's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


THC Therapeutics (THC Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
11700 W Charleston Boulevard, No. 73, Las Vegas, NV, USA, 89135
Website
THC Therapeutics Inc is a United States-based company. It is focused on developing dHydronator, a sanitizing herb dryer. The main function of the dHydronator is to accelerate the drying time of an herb while sanitizing it. The dHydronator can be used to dry a variety of herbs, and it has been specifically tested for use with cannabis. It will reduce the drying time for cannabis from 10-14 days down to less than 14 hours.
Executives
Hiro Tanaka director, officer: Vice President 3RD FLOOR, 207 REGENT STREET, LONDON X0 W1B 3HH
Smith Adrian J R director, officer: Chair of the Board 119 SPRINGLINE DRIVE, VERO BEACH FL 32963
Jamie Mann director, 10 percent owner, officer: CEO, CFO 3RD FLOOR, 207 REGENT STREET, LONDON X0 W1B 3HH
Eden Ho director, officer: CEO 701 XUANG MI HU ROAD, XI YUAN, FUTIAN, SHENZHEN F4 XXXXXX